Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12642017 | 0.92 | ALDH1A1 (0.50) | ALDH1A1CA2MAPTRECQLHSD11B1 | |
| SCHEMBL907404 | 0.88 | ALDH1A1 (0.47) | ALDH1A1CA2MAPTRECQLHSD11B1 | |
| Hydrochloric Acid SCHEMBL907268 | 0.87 | GAA (0.47) | ALDH1A1CA2MAPTRECQLHSD11B1 | |
| SCHEMBL17688654 | 0.87 | ALDH1A1 (0.48) | ALDH1A1CA2MAPTRECQLHSD11B1 | |
| SCHEMBL21151897 | 0.87 | ALDH1A1 (0.45) | ALDH1A1CA2MAPTRECQLHSD11B1 | |
| SCHEMBL13333146 | 0.87 | MAPT (0.50) | ALDH1A1MAPTRECQLHSD11B1KMT2A | |
| SCHEMBL907263 | 0.87 | CA12 (0.55) | ALDH1A1CA2MAPTRECQLHSD11B1 | |
| SCHEMBL23280908 | 0.85 | ALDH1A1 (0.44) | ALDH1A1CA2MAPTRECQLHSD11B1 | |
| SCHEMBL21151875 | 0.85 | ALDH1A1 (0.47) | ALDH1A1CA2MAPTRECQLHSD11B1 | |
| SCHEMBL17402095 | 0.85 | KMT2A (0.46) | ALDH1A1CA2MAPTRECQLHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3044236-A2 | MODIFIED ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF | Halozyme, Inc. (US) | 2016-07-20 | — | — | EP | claimed |
| WO-2015038984-A2 | MODIFIED ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF | HALOZYME, INC. (US) | 2015-03-19 | — | — | WO | claimed |
| US-20150071923-A1 | MODIFIED ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF | HALOZYME, INC. | 2015-03-12 | — | — | US | claimed |
| EP-4233909-A2 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Biotherapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022076905-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-3949969-A2 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | Silverback Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2022006340-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2022006327-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2021102332-A1 | TGFBETAR2 INHIBITOR-LRRC15 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| EP-3804765-A1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Biotherapeutics Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2021067644-A1 | COMBINATION THERAPY WITH IMMUNE STIMULATORY CONJUGATES | SILVERBACK THERAPEUTICS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| EP-2253330-B1 | Conjugated biological molecules and their preparation | POLYTHERICS LTD (GB) | 2015-08-19 | — | — | EP | disclosed |
| EP-2277550-B1 | Process for the preparation of conjugated biological molecules. | POLYTHERICS LTD (GB) | 2015-04-29 | — | — | EP | disclosed |
| WO-2011060018-A2 | COMPOSITIONS AND METHODS FOR USING PEPTIDES, MODIFIED PEPTIDES, PEPTIDOMIMETICS AND FIBRIN DERIVATIVES | IKARIA DEVELOPMENT SUBSIDIARY TWO LLC (US) | 2011-05-19 | — | — | WO | disclosed |
| EP-2277550-A1 | Conjugated biological molecules and their preparation | Polytherics Limited (GB) | 2011-01-26 | — | — | EP | disclosed |
| EP-2253330-A2 | Conjugated biological molecules and their preparation | Polytherics Limited (GB) | 2010-11-24 | — | — | EP | disclosed |
| EP-2133099-A2 | Conjugated biological molecules and their preparation | Polytherics Limited (GB) | 2009-12-16 | — | — | EP | disclosed |
| EP-1648518-B1 | CONJUGATED BIOLOGICAL MOLECULES AND THEIR PREPARATION | POLYTHERICS LTD (GB) | 2009-08-26 | — | — | EP | disclosed |
| EP-1648518-A2 | CONJUGATED BIOLOGICAL MOLECULES AND THEIR PREPARATION | Polytherics Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005007197-A2 | CONJUGATED BIOLOGICAL MOLECULES AND THEIR PREPARATION | POLYTHERICS LIMITED (GB) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150071923-A1 | MODIFIED ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB4 | ALDH1A1 3906/4885CA2 2624/4885MAPT 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.